RxDoctor Payments Data

Jessie Hibner

Family · Medford, ORNPI 1255853909

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 17 payments — averaging $65.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$143
  • Boehringer Ingelheim$125
  • GSK$125
  • Otsuka America Pharmaceutical, Inc.$123
  • Astellas Pharma US Inc$122
  • Amgen$121
  • plus $349 from 5 others

What the payments were for

  • Food & beverage$1,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,107 in reported general payments places this provider in the 85th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$77,996
Medicare patients
221
Services billed
1,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$67,577
XareltoRivaroxaban39$46,577
JardianceEmpagliflozin19$25,036
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,232
Atorvastatin Calcium347$3,821
Potassium Chloride115$3,333
Levothyroxine Sodium260$2,983
Losartan Potassium242$2,654
Metoprolol Succinate158$2,583
Albuterol Sulfate HfaAlbuterol Sulfate70$2,554
Estradiol49$2,017
Rosuvastatin Calcium112$1,672
SynthroidLevothyroxine Sodium17$1,667
Omeprazole124$1,568
Duloxetine Hcl43$1,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$125$25,03619 claims
AbbVieSynthroid$121$1,66717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,130 family providers in Oregon.

Other family in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →